Brief: Acadia Pharmaceuticals And Stoke Therapeutics Announce Collaboration To Pursue Multiple RNA-Based Treatments For Severe And Rare Genetic Neurodevelopmental Diseases
10/01/2022 12:11
Jan 10 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O :
* ACADIA PHARMACEUTICALS AND STOKE THERAPEUTICS ANNOUNCE COLLABORATION TO
PURSUE
MULTIPLE RNA-BASED TREATMENTS FOR SEVERE AND RARE GENETIC NEURODEVELOPMENTAL
DISEASES
* STOKE THERAPEUTICS -CO RECEIVES A $60 MILLION UPFRONT PAYMENT AND
POTENTIAL
MILESTONE PAYMENTS OF UP TO $907 MILLION AND ROYALTIES ON FUTURE SALES UNDER
DEAL
Source text for Eikon: ID:nBwbJNtxKa
Further company coverage: ACAD.O
Recent news on Stoke Therapeutics
See all newsBrief: Stoke Therapeutics Announces Inducement Grants
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics